AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Kadant, you really need to believe in the durability of its aftermarket parts and services, and in management’s ability to keep integrating acquisitions without overreaching. The latest quarter supports that story: record Q2 sales and earnings, plus slightly higher full-year revenue guidance, suggest the installed base is generating healthy recurring demand even as some big-ticket projects slip to the right. In the near term, the key catalyst remains whether that aftermarket strength can offset any prolonged hesitation in capital spending, especially given the stock’s relatively rich valuation multiples and modest recent share-price underperformance. The small trim to EPS guidance also nudges earnings execution risk a bit higher, which matters when insiders have been selling and returns on equity are only in the low double digits.
However, investors should be aware that premium pricing leaves less room for disappointment. Kadant's shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.Explore another fair value estimate on Kadant - why the stock might be worth 34% less than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com